Fulvestrant,palbociclib
pfizer
['palbo']
terrific work by the sonia investigators. using cdk4/6-inhibitors (mostly palbo) in 1l did not result in improvement of pfs2, os or qol compared to 2l use. however, 1l use increased the rate of g3 side effects by 42% and increased cost. poll below #asco23 
Medical Oncologist, Research Fellow @DanaFarber | @Harvard | PhD @LaStatale | former @IEOufficiale. Interested in breast oncology, HER2, ADCs & good music.